Uveal melanoma (UM) has a high mortality rate due to liver metastasis. The insulin-like growth factor-1 receptor (IGF-1R) is highly expressed in UM and has been shown to be associated with hepatic metastases. Targeting IGF signalling may be considered as a promising approach to inhibit the process of metastatic UM cells. Pristimerin (PRI) has been demonstrated to inhibit the growth of several cancer cells, but its role and underlying mechanisms in the IGF-1-induced UM cell proliferation are largely unknown. The present study examined the anti-proliferative effect of PRI on UM cells and its possible role in IGF-1R signalling transduction. MTT and clonogenic assays were used to determine the role of PRI in the proliferation of UM cells. Flow cytometry was performed to detect the effect of PRI on the cell cycle distribution of UM cells. Western blotting was carried out to assess the effects of PRI and IGF-1 on the IGF-1R phosphorylation and its downstream targets. The results indicated that IGF-1 promoted the UM cell proliferation and improved the level of IGF-1R phosphorylation, whereas PRI attenuated the effect of IGF-1. Interestingly, PRI could not only induce the G1 phase accumulation and reduce the G2 phase induced by IGF-1, but also could stimulate the expression of p21 and inhibit the expression of cyclin D1. Besides, PRI could attenuate the phosphorylations of Akt, mTOR and ERK1/2 induced by IGF-1. Furthermore, the molecular docking study also demonstrated that PRI had potential inhibitory effects on IGF-1R. Taken together, these results indicated that PRI could inhibit the proliferation of UM cells through down-regulation of phosphorylated IGF-1R and its downstream signalling. How to cite this article: Xie X, Xie S, Xie C, et al. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways.
| INTRODUC TI ON
Uveal melanoma (UM) is the most common intraocular cancer type in adults. 1 Although excellent local treatments are currently available, yet no significant progress has been made in changing the disease course. Uveal melanoma mainly metastasize to liver, and the ratio of patients developing liver metastases is approximately 50%. 2 To date, the underlying reason for the aggressive liver metastasis is still not known, and no treatment has been effective enough to prolong survival. Therefore, it's crucial to look for new molecular targets in order to provide more effective treatments for UM.
Insulin-like growth factor-1 is a strong mitogen, which can stimulate IGF-1R signalling, thereby playing an important role in the occurrence and growth of several cancers. [3] [4] [5] Recent studies have shown that the IGF-1 receptor was highly expressed in UM, and it has been related to tumour prognosis. 6 insulin-like growth factor-1 binds to its receptor, which activates intrinsic receptor tyrosine kinase activity leading to autophosphorylation of IGF-IR, and subsequently activates the downstream phosphatidylinositol 3′-kinase (PI3K)-Akt and mitogen-activated protein kinases (MAPK) signalling pathways. 7 In other cells, IGF-1R activation can mediate the activation of mammalian target of rapamycin (mTOR) both in vitro and in vivo, and the tyrosine phosphorylation of the endogenous mTOR can be induced by IGF-1 stimulation. 8 Insulin-like growth factor-1 receptor is also associated with the Akt/mTOR signalling activation and the extracellular signal-regulated kinase 1/2 (ERK1/2) in cancer cells. 9 However, mutant IGF-1 receptors with reduced autophosphorylation level show severely impaired mitogenic and tumourigenic activities. 10 Therefore, identification of the small molecules capable of inhibiting the tyrosine phosphorylation of IGF-1R subunit is the most effective way to prevent IGF-1R signalling in cancer cells. Pristimerin (PRI), a quinonemethide triterpenoid compound, has been widely used as antioxidant, antimalarial, anti-inflammatory and insecticidal agent. 11 In recent years, PRI has been shown to inhibit the growth in several cancer cells. [12] [13] [14] [15] However, the inhibitory effects of PRI on human UM cancer cells and its inhibitory potential in IGF-1 and IGF-1R-mediated tumourigenesis have not yet been investigated. Thus, the present work emphasizes the inhibitory effects of PRI on IGF-1R and downstream signal transduction.
| MATERIAL S AND ME THODS

| Materials
Pristimerin (purity >99%) was obtained from Chengdu PureChem-Standard Co., Ltd; IGF-1, poly-L-lysine, bovine serum albumin, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were commercially obtained from Sigma; Antibiotics, Dulbecco's Modified Eagle's Medium (DMEM), trypsin and foetal bovine serum (FBS) were purchased from Gibco-BRL;
Anti-β-actin, anti-phospho-IGF-1R (Tyr1135/Tyr1136), anti-IGF-1R, anti-p21 Waf1/Cip1 (p21) and anti-Cyclin D1 were from Signalway Antibody. Anti-phospho-Akt (Thr308), anti-ERK1/2, anti-phospho-Akt (Ser473), anti-phospho-mTOR (Ser338), anti-Akt and anti-phospho-ERK1/2 (Thr202/Tyr204) were from cell signalling technology.
| Cell culture
Human uveal melanoma cell lines (UM cells) were obtained from Shanghai Bioleaf Biotech Co., Ltd. And they were maintained in DMEM supplemented with 10% (v/v) FBS, 100 µg/mL streptomycin and 100 U/mL penicillin and incubated at 37°C under 5% CO 2 . The culture medium was changed every 3 days.
| MTT assay
Cell viability was determined by MTT assay according to the method described in our previous study. 16 Briefly, the cells suspended in the medium were seeded in 96-well plates with a density of 1 × 10 4 cells/ well. After being grown at 37°C in a humidified incubator with 5% CO 2 for 24 hours, the cells were incubated with PRI or/and IGF-1 for another 24 hours. After treatment, 10 µL of MTT (5 mg/mL) was added to each well, and the mixture was incubated for 2 hours at 37°C. Then, the MTT reagent was removed, and DMSO (100 μL per well) was added to dissolve the formazan crystals. After shaking the mixture at room temperature for 10 minutes, absorbance was measured at 570 nm using a microplate reader (BioTek Instruments). Results were expressed as the percentage of the absorbance of control cells, which was set at 100%.
| Clonogenic assay
Uveal melanoma cells (200/well) were seeded in 6-well plates for 7 days after the treatment with PRI and/or IGF-1. After completing the experiment, the cell growth medium was removed, and the cells were washed with phosphate-buffered saline (PBS). Then they were fixed with 4% paraformaldehyde, and the colonies were stained with crystal violet (0.2%). The colonies of more than 50 cells were counted. All experiments were performed at least three times.
| Flow cytometry assay
Flow cytometry was carried out following the protocols routinely used in our laboratory. 17 Briefly, the cells were seeded into 6-well plates and treated with IGF-1 in the presence or absence of PRI for 24 hours. After that, the cells were harvested and washed twice with ice-cold PBS. Then they were fixed overnight in ice-cold 70% ethanol and stained with a mixture of Ribonuclease A (RNase A) and
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Akt, mTOR, pristimerin, IGF-1, uveal melanoma, ERK1/2 propidium iodide (PI). The stained cells were analysed by flow cytometry, and the experiments were repeated three times.
| Western blotting analysis
Western blotting analysis was performed as our previously described method. 18 Cells were lysed with ice-cold RIPA lysis buffer, and the corresponding protein concentration was determined by a BCA protein assay kit under the manufacturer's instructions. Equal amounts of lysate protein (20 μg/lane) were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with 10% polyacrylamide gels and then electrophoretically transferred to nitrocellulose membranes. After transfer, the nitrocellulose blots were blocked with 3% BSA in PBST buffer (PBS with 0.01% Tween 20, PH 7.4) and incubated with primary antibodies in PBST containing 1% BSA overnight at 4°C. Immunoreactivity was determined using sequential incubation with horseradish peroxidase-conjugated secondary antibodies and detected by the enhanced chemiluminescence (ECL) technique. 
| Molecular docking modelling assay
| Statistical analysis
All the results were expressed as means ± SEM (n = 3-5 times).
Analysis of variance (ANOVA) was used to analyse the differences between the groups, followed by the Tukey-Kramer or Dunnett's multi-comparison test with Predictive Analytics Software (PASW) (SPSS Inc.). P < .05 was regarded as statistically significant. Figure 1A shows the chemical structure of PRI. The inhibitory activity of PRI on UM cells was investigated by the cell viability assay. As can be seen in Figure 1B , PRI can inhibit cell proliferation in a dosedependent manner and significantly reduce the number of cultured live cells. In order to determine the possible effect of IGF-1 on cancer cell growth, UM cells were first treated with IGF-1 at different concentrations (3-300 ng/mL), and the MTT assay was carried out to detect the cell growth. The results indicated that IGF-1 improved the cell viability in a dose-dependent manner with the maximum effect at 100 ng/mL ( Figure 1C ). Thus, this concentration was selected for further experiments. To confirm the inhibitory effect of PRI on cell viability, a colony formation assay was performed. The results from the MTT assay showed that PRI inhibited cell proliferation induced by IGF-1 in a dose-dependent manner ( Figure 1D ) after the cells were seeded in 6-well plates and colonies were formed for 1 week.
| RE SULTS
| PRI suppressed proliferation and colony formation induced by IGF-1 in UM cells
As shown in Figure 1E , PRI (1 μmol/L) significantly inhibited colony formation of UM cells and showed a very significant difference in comparison to the control group. These results were in line with the MTT assay. In contrast, IGF-1 treatment displayed an increased number of colonies, but PRI significantly inhibited colony formation induced by IGF-1 ( Figure 1F ). Overall, these results indicated that PRI could inhibit the UM cell proliferation induced by IGF-1.
| PRI regulated the cell cycle distribution of UM cells
Next, the effect of PRI on the cell cycle distribution of UM cells was examined. After treatment with PRI (1 μmol/L) for 24 hours, the UM cells were processed and stained with propidium iodide (PI). Then, a flow cytometry assay was performed to determine the cell cycle distribution. From Figure 2A , it can be seen that IGF-1 induced S phase accumulation, but cells in the G1 phase were diminished, and PRI reversed the effect of IGF-1. Treatment with PRI (1 μmol/L) alone also induced G1 phase accumulation and reduced G2 phase accumulation.
P21 and Cyclin D1 are key regulators in cell cycles. Thus, western blotting was also performed to investigate the involvement of IGF-1 in regulating the expression of p21 and cyclin D1. It can be seen from the Figure 2B ,C) that treatment with IGF-1 boosted the expression of cyclin D1 but had no effect on p21, while PRI prevented the expression of cyclin D1 and enhanced the expression of p21 in a dosedependent manner. This demonstrated that PRI could affect UM cell cycle distribution as well as p21 and cyclin D1 expression.
| PRI inhibited IGF-1-induced tyrosine phosphorylation of IGF-1R in UM cells
Previous studies indicated that IGF-1 could prompt the UM cell proliferation. Accordingly, the signalling pathways responsible for this effect were investigated in present study. We hypothesized that the tyrosine phosphorylation of IGF-1R stimulated by IGF-1 is the initial and essential step of IGF-1 signalling.
At the beginning of the experiment, IGF-1 (100 ng/mL) was used to stimulate the tyrosine phosphorylation of IGF-1R at different time points from 5 to 80 minutes ( Figure 3A,B) . The results showed that the phosphorylation levels of these two kinases induced by IGF-1 were significantly increased within 20 minutes and peaked at 40-80 minutes.
Consistently, the IGF-1 also induced the phosphorylation of IGF-1R in a concentration-dependent manner (Figure 3C,D) . The tyrosine phosphorylation of IGF-1R in UM cells was observed at a concentration of 3 ng/mL of IGF-1 and increased as the concentration of IGF-1 increased to a maximum of 30 ng/mL. We then explored whether PRI could inhibit the IGF-1R activation in UM cells. As shown in Figure 4A ,B, after co-treatment of cells with 
| PRI suppressed IGF-1-induced IGF-1R signalling pathway
As PI3K/Akt/mTOR and MAPK pathways are the main downstream signalling pathways of IGF-1R, we further determined whether they were participated in the anti-proliferative action of PRI in UM cells stimulated by IGF-1. After treating UM cells with IGF-1 at various time points (0-80 minutes) or stimulating them with 1-100 ng/mL of IGF-1 for 40 minutes, the extent of phosphorylation of mTOR, Akt and ERK1/2 was determined by western blotting. As shown in Then the UM cells were treated with 1 μmol/L PRI at various time points (0-80 minutes) and stimulated with 100 ng/mL of IGF-1 for 40 minutes. The results indicated that PRI decreased the IGF-1induced mTOR, Akt and ERK1/2 phosphorylation in a time-dependent manner ( Figure 6A,B) . Besides, the dose-course action of PRI was also tested in present work. UM cells were pre-treated with PRI at various concentrations (0.1-3 μmol/L) for 40 minutes and then incubated with IGF-1 (100 ng/mL) for 40 minutes. As shown in Figure 6C,D) . These results suggested that PRI could not only inhibit the phosphorylation of IGF-1R but also could inhibit the IGF-1R-mediated signalling pathways.
| Identifying PRI as a novel potential IGF-1R kinase inhibitor
In order to validate whether PRI is a novel potential IGF-1R kinase inhibitor for cancer therapy, a molecular modelling study was carried out using the MOE 2015.10 software package. The X-ray crystal structure of the IGF-1R kinase combined with NVP-AEW541 (PDB code 5HZN) was used to establish the starting model of IGF-1R.
F I G U R E 2 PRI affected the cell cycle progression and the downstream target genes in UM cells. A, UM cells were treated with PRI
(1 μmol/L) for 40 min and then were treated with or without IGF-1 in a serum-free medium for 40 min. Cells were stained with propidium iodide (PI) and analysed using a flow cytometer. The cell cycle distribution (%) was calculated using FlowJo 7.6. B, Pre-treatment of UM cells with indicated concentration of PRI for 40 min was followed by treatment with or without 100 ng/mL IGF-1 for 40 min. The expressions of cyclin D1 and p21 were determined by western blotting. C, Quantification of the immunoblot was performed using densitometric analysis. 
| D ISCUSS I ON
Insulin-like growth factor-1 receptor signalling plays a crucial role in the cell proliferation, migration and cellular invasion of basement membranes. Accordingly, IGF-1R signalling was regarded as a promising anti-tumour target, which has been widely studied in clinical trials for different types of tumours including lung cancer, prostate cancer and breast cancer. 5 In recent years, using either IGF-1R targeting antibodies or small molecule inhibitors toward the IGF-1R kinase has been extensively studied. [19] [20] [21] High levels of IGF-1R in UM are closely related to metastatic progression. 22 Thus, suppression of IGF-1R provides an effective therapeutic approach to decrease the proliferation of UM cells, especially for cancer cells that have higher expression.
Autophosphorylation and tyrosine kinase activity of IGF-1R receptors play a crucial role in their signalling functions. 23 Therefore, the improved activity of tyrosine kinases was associated with many cancers and other proliferative diseases. 24 The signalling pathways and tyrosine kinases in which they participate have thus been identified as promising targets for drug design. 24, 25 In the present study, Previous studies indicated that the IGF-1R signalling blocked in vitro by the tyrosine kinase inhibitor could inhibit downstream proliferative signalling through Akt and lead to cell death. 26, 27 In the present study, PRI obviously decreased the tyrosine phosphorylation of IGF-1R. Moreover, it also inhibited the activation of Akt, mTOR and ERK1/2. In UM tumours, the IGF-1R/PI3K/Akt pathway is constitutively activated, 28 and the elevated phosphorylation levels of Akt are related to poor prognosis in most UM. 29, 30 Thus, the IGF-1R/PI3K/ Akt pathway has been regarded as a main target, which is being evaluated as a treatment to further illustrate the importance of targeting activated signalling pathways in different metastatic diseases. Recent studies have shown that mTOR mutations usually occur in melanoma patients and show more negative therapeutic prognosis. Clinical trials with the inhibitors of PI3K/AKT/mTOR pathways may be favourable for melanoma patients with specific mTOR mutations. 31 In the present work, it was found that IGF-1 improved the UM cell Hence, this result was consistent with the finding that treatment of melanoma with selected signalling kinase inhibitors can effectively decrease proliferation and increase expression of cell cycle inhibitors. 33 According to the aforementioned molecular docking suggestions, PRI was a potent inhibitor of IGF-1R, which is consistent with previous reports that compounds with good binding affinity to the IGF-1R tyrosine kinase have potent activity in the inhibition of cell growth. 20 All these results confirm the fact that PRI inhibits IGF-1R and its downstream signalling pathways.
However, future studies including determining whether overex- 
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